Figure 1.

Therapeutic targeting of Tregs. The targeting of Tregs for therapeutic purposes has been proposed for various pathologies. Experimental models have provided evidence showing that reducing Tregs can result in a decrease in tumor growth and enhanced efficacy of tumor immunotherapy. In such cases, suppressing the CD4⁺CD25⁺FOXP3⁺ Treg population could prove beneficial (right side of the scale). However, in the context of autoimmune disease, inflammatory disorders, and graft rejection, polyclonal expansion and proliferation of CD4⁺CD25⁺FOXP3⁺ Tregs may have potential utility by mitigating autoimmune attack and augmenting Treg-mediated immunosuppression (left side of the scale).